Association of XPD Asp312Asn single nucleotide polymorphisms with oxaliplatin based chemotherapy

Abstract

Objective This study was to determine the role of the Xeroderma pigmentosum group D (XPD) Asp312Asn polymorphism in predicting response to Oxaliplatin based chemotherapies and survival in patients with metastatic colorectal cancer. Methods This study enrolled a total of 106 patients treated with FOLFOX4 (n=72) or XELOX (n=34) regimen. The genotype of XPD Asp312Asn was analyzed by TaqMan probe based real-Time polymerase chain reaction (PCR). Logistic regression was used to predict the response to the treatments. Cox proportion hazards models and Kaplan-Meier method were applied to predict the survival. Results The effective rate of chemotherapy in 106 patients with colorectal cancer was 57.6%(61/106). There was no significant difference in the distribution of G/G, G/A and A/A genotypes between the two groups (P>0.05). Multivariate survival analysis showed that the survival time of patients with A/A genotype, carcinoembryonic antigen (CEA) (>5 ng/ml) and age (>65 years) was relatively short, with statistical significance (P<0.05). Conclusions XPD Asp312Asn single nucleic acid polymorphism can be used as a predictor of survival in patients with metastatic colorectal cancer, but it is not associated with oxaliplatin sensitivity and needs further study. Key words: Colorectal neoplasms/DT; Antineoplastic combined chemotherapy protocols; Organoplatinum compounds/AD; Xeroderma pigmentosum group D protein/GE; Polymorphism, single nucleotide